Notice of Conclusion of Basic Agreement on Business Alliance with Shionogi Pharma Co., Ltd. | News | Reborna Biosciences, Inc.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/HMFQLO7DTFOJVFU3APRGY6JUEI.jpg "Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval | Reuters")
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval | Reuters
Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022｜Shionogi & Co., Ltd.
Shionogi, GARDP and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries | GARDP
SyntheticGestalt | Automatic Invention
Press Release
Press Release
Contribution to the Global Health Innovative Technology Fund (GHIT Fund) for the Third Phase
Exclusive license agreement for a sensitive virus detection method between Hokkaido University and SHIONOGI | Hokkaido University
Japanese panel postpones verdict on Shionogi's COVID pill until July - The Japan Times
Commitment to Fight COVID-19 | Sustainability | Shionogi & Co., Ltd.
SHIONOGI (@SHIONOGI_JP) / X
Shionogi seeks Japan approval for COVID-19 vaccine | The Asahi Shimbun: Breaking News, Japan News and Analysis
Shionogi seeks approval for Japan's first domestic COVID pill - The Japan Times
NIH Trial to Evaluate Shionogi Antiviral in Adults Hospitalized with COVID-19 | NIAID: National Institute of Allergy and Infectious Diseases
Shionogi Inc. (U.S.) on LinkedIn: Shionogi & Co., Ltd. (our parent company in Japan) has released positive…
Press Release
Shionogi Inc. (U.S.) on LinkedIn: Shionogi & Co., Ltd. (our parent company in Japan) has released positive…
Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio
Positive Results from Phase 3 Clinical Trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan｜ SHIONOGI
Expansion of “Gamma Wave Sound” Initiatives by Pixie Dust Technologies, Inc., Shionogi & Co., Ltd. and
Press Release
A4 Basic Template
Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Juniper Therapeutics and SAR approval in Singapore regardi
